Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.
Vaccine Adjuvants Market Revenue Outlook: What CAGR Lies Ahead Through 2030?
The vaccine adjuvants market has experienced robust expansion in recent years. It is projected to grow from $2.01 billion in 2025 to $2.18 billion in 2026, at a compound annual growth rate (CAGR) of 8.4%. Historically, this market’s expansion can be attributed to the increasing prevalence of infectious diseases, greater government funding for vaccine research, the rising adoption of traditional vaccines, the development of oil-in-water and water-in-oil emulsions, and technological advancements in pathogen component adjuvants.
The vaccine adjuvants market size is anticipated to undergo significant expansion in the coming years, with its valuation expected to climb to $3.13 billion in 2030, marking a compound annual growth rate (CAGR) of 9.5%. This projected growth during the forecast period stems from factors such as increasing demand for human and veterinary vaccines, a growing emphasis on immunotherapies for cancer and infectious diseases, innovations in nanoparticle and liposome adjuvants, regulatory encouragement for novel adjuvants, and the broadening of biologics manufacturing infrastructure. Key developments expected within this period include personalized vaccine adjuvant development, the introduction of novel immunostimulatory compounds, multi-disease targeted adjuvants, enhanced safety and efficacy profiles, and rapid vaccine formulation platforms.
Get A Free Sample Report With In-Depth Market Insights:
Vaccine Adjuvants Market Growth Backed By Core Demand Fundamentals
Increased investment in vaccine research is anticipated to boost the expansion of the vaccine adjuvants market. These activities encompass extensive scientific efforts focused on creating, evaluating, and enhancing vaccines to combat infectious diseases. Such research is crucial for identifying, assessing, and refining possible adjuvant candidates derived from diverse origins, such as natural substances, man-made compounds, or even microorganisms like bacteria and viruses. As an illustration, in October 2023, the United States Department of Health and Human Services, a US federal agency delivering key human services, unveiled Project NextGen. This initiative involved a $500 million investment designated for initiating the development of phase 2b clinical trial blueprints and pioneering technologies for advanced next-generation vaccination and treatment solutions. Consequently, the rising financial support for vaccine research is propelling the expansion of the vaccine adjuvants market.
Vaccine Adjuvants Market Segment Landscape: Which Areas Lead Development?
The vaccine adjuvants market covered in this report is segmented –
1) By Product Type: Adjuvant Emulsions, Pathogen Components, Particulate Adjuvants, Combination Adjuvants, Other Product Types
2) By Route of Application: Human Vaccine Adjuvants, Veterinary Vaccine Adjuvants
3) By Route of Administration: Oral, Intramuscular, Intranasal, Subcutaneous, Intradermal
4) By Disease: Cancer, Infectious Diseases, Other Diseases
Subsegments:
1) By Adjuvant Emulsions: Oil-In-Water Emulsions, Water-In-Oil Emulsions
2) By Pathogen Components: Bacterial Components, Viral Components
3) By Particulate Adjuvants: Liposomes, Nanoparticles, Microparticles
4) By Combination Adjuvants: Mixed Emulsions, Multiple Component Systems
5) By Other Product Types: Synthetic Adjuvants, Natural Adjuvants
Vaccine Adjuvants Market Growth Trends Reshaping The Competitive Landscape
Leading companies in the vaccine adjuvants market are directing their efforts toward technological advancements, including cultured-plant-cell QS-21 (cpcQS-21), to satisfy the rising demand for more sustainable and scalable production of potent immune-stimulatory adjuvants. QS-21 is a powerful saponin adjuvant traditionally extracted from Quillaja saponaria tree bark; distinct from conventional aluminum-based adjuvants, QS-21 activates both robust antibody and cellular immune responses, yet its availability is restricted by limited tree bark supply and varying quality. In August 2024, SaponiQx, a US-based biomanufacturing company, launched STIMULON cultured plant cell QS-21, a cpcQS-21 adjuvant now offered for commercial acquisition through InvivoGen. This product is manufactured using plant cell culture rather than tree bark, ensuring a consistent and scalable supply; it also provides high purity, batch-to-batch uniformity, and a reduced environmental impact. Functionally, STIMULON cpcQS-21 maintains the identical immunostimulatory potency as tree-derived QS-21 in driving both humoral and cellular immune responses, making it appropriate for use in vaccines targeting infectious diseases such as malaria, shingles, and RSV.
Vaccine Adjuvants Market Industry Leaders And Competitive Landscape
Major companies operating in the vaccine adjuvants market are GlaxoSmithKline Plc., Novavax Inc., Agenus Inc., CSL Limited, Adjuvatis, Merck KGaA, Seppic Inc., Virometix AG, Adjuvance Technologies Inc., Novartis AG, Vaxine Pty Ltd., Statens Serum Institute, GSK Vaccines, VaxLiant LLC, VaxForm LLC, Serum Institute of India, Dynavax Technologies Corporation, Vaxcyte Inc., VBI Vaccines Inc., Medicago Inc.
View The Full Vaccine Adjuvants Market Report:
Vaccine Adjuvants Market Regional Distribution: Which Areas Power Market Growth?
North America was the largest region in the vaccine adjuvants market in 2025.Asia-Pacific is expected to be the fastest-growing region in the global vaccine adjuvants market report during the forecast period. The regions covered in the vaccine adjuvants market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
